Stock Analiz

Bioventus Inc. (BVS) stock forecast and price target

Price $10.66 · data as of November 13, 2026

12-month price target

Average target$16.60
Upside / downside+55.7%
Analysts5
ConsensusStrong buy
Low $15.00Average $16.60High $18.00

Gold marker: average target · white marker: today’s price ($10.66)

Analyst ratings

Strong buy 2Buy 3Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$0.77+12.9%$595M
Next fiscal year
ends December 31, 2027
$0.89+15.6%$633M
Next quarter
ends December 31, 2026
$0.24−1.7%$166M
Quarter after
ends March 31, 2027
$0.15+0.0%$139M

Consensus of the analysts covering Bioventus, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.

Our model vs. Wall Street

Analysts see 55.7% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Bioventus’s intrinsic value about 50% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Bioventus stock price target?

The average 12-month target from 5 analysts is $16.60, 55.7% above the current price of $10.66 Targets range from $15.00 to $18.00.

Is Bioventus a buy according to analysts?

The consensus rating is “Strong buy” (2 strong buy, 3 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is Bioventus expected to earn?

Analysts expect EPS of $0.77 for the fiscal year ending December 31, 2026 and $0.89 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.